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An outbreak of hantavirus pulmonary syndrome
occurred in the province of Los Santos, Panama, in late
1999 and early 2000. Eleven cases were identified; 9 were
confirmed by serology. Three cases were fatal; however, no
confirmed case-patient died. Case-neighborhood serologic
surveys resulted in an overall hantavirus antibody preva-
lence of 13% among household and neighborhood mem-
bers from the outbreak foci. Epidemiologic investigations
did not suggest person-to-person transmission of han-
tavirus infection. By use of Sin Nombre virus antigen, han-
tavirus antibodies were detected in Oligoryzomys
fulvescens and  Zygodontomys brevicauda cherriei. This
outbreak resulted in the first documented cases of human
hantavirus infections in Central America.
H
antavirus pulmonary syndrome (HPS) is an infectious
disease typically characterized by fever, myalgia, and
headache and followed by dyspnea, noncardiogenic pul-
monary edema, hypotension, and shock (1,2). Common
laboratory findings include elevated hematocrit, leukocy-
tosis with the presence of immunoblasts, and thrombocy-
topenia (3,4). The case-fatality rate can be as high as 52%
(5). The etiologic agent of HPS is any one of several han-
taviruses carried by rodent hosts belonging to the family
Muridae, subfamily Sigmodontinae (6). Hantaviruses are
most often transmitted to humans through the inhalation of
infectious rodent feces, urine, or saliva. However, strain-
specific virus transmission may occur from person to per-
son (7–9). 
HPS was first recognized in 1993 during an outbreak of
severe respiratory disease in the Four Corners Region of
the United States (10,11). Since then, 363 cases of HPS
have been confirmed in the United States (12). Sin Nombre
virus (SNV) was the first HPS-causing pathogen identi-
fied; its primary rodent reservoir host is the deer mouse,
Peromyscus maniculatus (13,14). However, four other
hantaviruses, Bayou virus, Black Creek Canal virus, New
York virus, and Monongahela virus, each with a different
rodent reservoir, have been characterized in the United
States and associated with HPS (6,15–21). 
Since 1993, HPS has also been reported and confirmed
in six countries in South America—Argentina, Bolivia,
Brazil, Chile, Paraguay, and Uruguay (6,9,22–30). Several
distinct hantaviruses have been associated with HPS,
including Andes virus (Argentina, Bolivia, Chile, and
Uruguay), Bermejo virus (Bolivia), Juquitiba virus
(Brazil), Laguna Negra virus (Bolivia, Paraguay),
Lechiguanas virus (Argentina), and Oran virus (Argentina)
(22,23,25,28,30,31). 
Before 2000, no human hantavirus infections had been
reported in Central America. However, in February 2000,
health officials in Panama reported a cluster of acute respi-
ratory illnesses in residents of the district of Las Tablas in
Los Santos Province from late December 1999 to February
2000 (32). Human illness was characterized by a febrile
prodrome with rapid progression to moderate-to-severe
respiratory distress. Serum specimens from three of four
patients had immunoglobulin (Ig) M and IgG antibodies to
SNV. In February and March 2000, an outbreak investiga-
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Memorial Institute for Health Studies (Panama City), the
U.S. Centers for Disease Control and Prevention (Atlanta,
GA), and the Pan American Health Organization was con-
ducted in collaboration with local medical and public
health officials. Sequence analysis of virus genome from
human serum samples and rodent tissue led to the identifi-
cation of a novel hantavirus, Choclo virus, as the cause
of HPS in this outbreak (33). This report summarizes the
clinical, epidemiologic, and environmental findings of the
investigation.
Materials and Methods
Case Definition
A suspected case of HPS was defined as fever (temper-
ature >38.3°C) and unexplained acute respiratory distress
requiring supplemental oxygen, with radiographic evidence
of acute respiratory distress syndrome or bilateral intersti-
tial pulmonary infiltrates (34). A suspected case was also
defined as an unexplained respiratory illness resulting in
death, with a postmortem examination indicating noncar-
diogenic pulmonary edema without identifiable cause (34).
A confirmed case of HPS was defined as a clinically com-
patible illness plus the presence of one of the following; 1)
hantavirus-specific IgM antibodies in acute-phase serum,
2) hantavirus-specific nucleic acid sequences by reverse
transcriptase polymerase chain reaction (RT-PCR), or 3)
hantavirus-specific antigen by immunohistochemistry (34).
Case Finding and Characterization
At visits to two hospitals in Panama City and one in the
Las Tablas District that admitted patients with suspected
HPS, hospitalized patients were examined and interviewed
when possible, and medical charts were reviewed. To iden-
tify past HPS patients, retrospective chart reviews were
conducted on admissions dating back to August 1999 at
these hospitals. In addition, medical records of any previ-
ous or current suspected HPS patients admitted to other
district hospitals in the Las Tablas Province were obtained
and reviewed. Clinical case information was collected on a
standard abstraction form. 
To monitor the spread of disease in Las Tablas and
other areas of Los Santos Province, an outbreak communi-
cations center was established at the Ministry of Health in
Panama City and staffed by physicians, public health offi-
cials, and health educators. Operations of this center
included 1) passive surveillance for suspected cases of
HPS, 2) a public hotline that addressed symptoms and
signs of HPS and methods of prevention, and 3) nation-
wide distribution of HPS educational materials. Staff
physicians also called hospitals throughout Panama to pro-
mote awareness of HPS among medical providers. 
Community Surveys
Surveys for hantavirus antibodies were conducted on
March 5, 2000, in six neighborhoods in the Las Tablas
District and one in the Guarare District in which confirmed
HPS patients resided. The primary objectives of the sur-
veys were to determine the prevalence of hantavirus infec-
tion within households and neighborhoods of case-patients
and the frequency of mild and asymptomatic infection.
Approximately 10–15 households, including the case-
patient household, were sampled in each of the seven
neighborhoods. Teams composed of public health officials,
nurses, and phlebotomists visited each neighborhood. The
day before the survey, pamphlets explaining the survey in
Spanish were given to each household that had agreed to
participate. All participants were administered a standard
questionnaire that asked about demographic characteris-
tics, illness history, and rodent exposure. Team members
were familiarized with the questionnaire before the survey
started. A10-mLblood specimen (3–5 mLfor children) for
hantavirus serologic testing was collected from each inter-
viewed participant. 
Hospital Survey
A hospital survey was conducted March 9–10, 2000,
among healthcare workers who cared for confirmed HPS
patients at a major hospital in Panama City. This hospital
received most of its cases from Las Tablas. The objectives
of the survey were to 1) serologically determine exposure
to hantavirus among doctors, nurses, respiratory therapists,
physiotherapists, and nurses’ aides who provided direct
care to confirmed HPS patients and 2) assess whether per-
son-to-person transmission occurred. Medical staff who
provided direct medical care (i.e., <1 m from the patient)
to infected patients in the emergency room and medical
intensive care unit were compared with those in the coro-
nary or neurologic intensive care units who had no expo-
sure to case-patients. A standard self-administered
questionnaire was used to inquire about timing and amount
of exposures, specific types of exposures, and precaution-
ary measures taken. A 10-mL blood specimen for han-
tavirus serologic testing was collected from each surveyed
participant.
Rodent Investigation
Small mammals were sampled to determine potential
hantavirus reservoir hosts. Primary sampling methods
were trapping and collecting small mammals around
households of confirmed and suspected HPS patients and
from two uninhabited locations in Los Santos. The habitat
of each trapping area was described. Small mammals were
initially identified in the field on the basis of external char-
acteristics and standard keys for the region. Definitive
identification that used cranial characteristics was per-
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of New Mexico, where voucher specimens from these
small mammals are currently archived. Liver, kidney,
spleen, lung, heart, and a whole blood sample were collect-
ed from each trapped rodent for diagnostic testing, and car-
casses were preserved for rodent speciation. Trapping and
sampling were performed according to established safety
protocols (35). Panamanian team members were trained to
trap and observe safety precautions when handling poten-
tially infectious rodents.
Diagnostic Testing
All available serum specimens from suspected HPS
patients were tested for IgM antibodies by using an IgM-
capture format and inactivated SNV antigen and for IgG
antibodies by an indirect enzyme-linked immunosorbent
assay (ELISA) as previously described (11). Serum sam-
ples from survey participants, rodents, and other small
mammals were tested for IgG antibodies by using SNV
antigens. IgG-positive survey participants were also tested
for IgM antibodies by use of SNV antigens. Positive find-
ings with SNV antigens in the IgG- or IgM-capture
ELISAs indicate infections with New World hantaviruses
rather than with SNV specifically. 
Results
Characteristics of HPS Patients
Eleven case-patients with suspected HPS were identi-
fied and reported to the Panamanian Ministry of Health
from December 25, 1999, to February 29, 2000 (Figure 1).
Three patients (25%) died; neither serum nor tissue sam-
ples were available for diagnostic testing from these three
patients. The remaining eight cases were confirmed by the
presence of IgM against hantavirus in at least two separate
serum specimens from patients; all eight also had IgG anti-
bodies, with five demonstrating IgG seroconversion after
the first specimen. One additional patient, whose onset of
illness was August 24, 1999, was identified retrospective-
ly. Although acute-phase clinical specimens were not
available for testing, review of medical records indicated
that her illness was clinically compatible with HPS, and
her IgG titer in February 2000 was elevated (6,400). She
was subsequently confirmed as the ninth HPS patient.
The median age of the 12 patients was 42 years (range
26–58 years); seven (58%) were women. The primary
occupation of patients was as follows: secretary (2), house-
wife (2), truck driver/transporter (2), electrician (1), field
pump worker (1), seamstress (1), teacher (1), security
guard (1), and unidentified (1). 
All cases occurred in the Las Tablas, Guarare, and
Tonosi Districts of Los Santos Province. In Las Tablas and
Guarare, eight towns had at least one patient with suspect-
ed HPS, and seven had one or more confirmed patients
(Table 1). Two cases, one suspected and one confirmed,
were identified in Tonosi. No clustering of cases occurred
at the household level. 
Two patients denied handling or cleaning up rodent
excreta before their illnesses, while a third admitted fre-
quently killing and handling rodents. In interviews, family
members of all case-patients from Las Tablas District
noted marked increases in the number of rodents in and
around the home from November 1999 to February 2000.
Clinical Description of Confirmed HPS Patients
The spectrum of preadmission symptoms of the nine
confirmed patients is documented in Table 2. The mean
temperature on admission was 38.0°C (n = 6, range
37.3°C–39.6°C). The median systolic and diastolic blood
pressure values were 100 mm Hg (n = 9, range 80–130)
and 63 mm Hg (n = 9, range 50–80), respectively. The
median pulse rate was 102/min (n = 8, range 60–172). The
median respiratory rate was 23/min (n = 8, range 14–36).
No patient was unconscious or cyanotic on admission. A
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Figure 1. Location of districts in Los Santos Province, Republic of
Panama, in which hantavirus cases occurred in 1999 and 2000. 
Table 1. Geographic distribution of suspected and confirmed HPS 
cases, Los Santos Province, Panama, August 1999–February 
2000
a
Town District 
No. confirmed 
cases 
No. suspected 
cases 
El Cocal  Las Tablas  1  0 
La Tronosa  Las Tablas  0  1 
Las Tablas  Las Tablas  1  0 
Los Angeles  Las Tablas  1  0 
San Jose  Las Tablas  2  0 
Santo Domingo  Las Tablas  1  0 
Bella Vista  Guarare  1  0 
La Enea  Guarare  1  1 
Las Llanas  Tonosi  1  1 
aHPS, hantavirus pulmonary syndrome. temperature of >38.5°C was documented in all patients at
some time during hospitalization. Seven of nine patients
were hypotensive during their illness (median lowest sys-
tolic blood pressure = 90, range 50–100), and three
required inotropic therapy.
Laboratory values at admission and during hospitaliza-
tion are listed in Table 3. Eight of nine patients were
thrombocytopenic either on admission or at some time dur-
ing hospitalization. Five of nine had hematuria (urine ery-
throctyes >10 per high power field, while four of nine had
moderate proteinuria (<2+ on urine dipstick). Evidence of
renal function abnormalities was present in three of nine
patients whose serum creatinine levels were >2.0 mg/dL. 
Three of nine patients had aspartate aminotransferase
>500 U/L, alanine aminotransferase >300 U/L, total biliru-
bin  >1.5 mg/dL, and direct bilirubin >1.0 mg/dL. Two
patients had clinical evidence of liver disease—one with
hepatomegaly and the other with scleral icterus.
Hematemesis, melena, and coagulopathy (prothrombin
time = 22 s, partial thromboplastin time = 167 s, fibrino-
gen = 161 mg/dL) also developed in one patient. Two of
the three patients also had elevated serum amylase values
(294 and 437 U/dL).
Seven of nine patients had chest x-ray examinations on
admission. All had evidence of bilateral infiltrates, and one
of seven had a radiographic pattern suggestive of pul-
monary edema. Two patients who did not have chest x-ray
examinations on admission subsequently were found to
have bilateral interstitial infiltrates radiographically.
Pulmonary edema of varying severity developed in four
patients during the course of their illnesses; pleural effu-
sions also occurred in three of these patients, and they
were intubated within 24 to 72 hours after admission. 
Community Survey
Interviews and serum specimens were obtained from
311 (83%) of 376 residents of seven different neighbor-
hoods of Las Tablas and Guarare Districts in which con-
firmed HPS patients were identified. These 311 survey
participants represented 119 households. A minimum of
one blood specimen was obtained from each household.
Forty (13%) of 311 survey participants had IgG against
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Table 2. Symptoms on admission in nine patients with laboratory-
confirmed hantavirus pulmonary syndrome, Los Santos Province, 
Panama, August 1999–February 2000 
Symptom No.  (%) 
Fever 9  (100) 
Dyspnea  8 ( 89) 
Myalgia  8 ( 89) 
Cough  7 ( 78) 
Malaise  6 ( 67) 
Vomiting  5 ( 56) 
Nausea  4 ( 44) 
Headache  4 ( 44) 
Arthralgia  4 ( 44) 
Weakness  4 ( 44) 
Lower back pain  3 ( 33) 
Abdominal pain  2 ( 22) 
Chest pain  2 ( 22) 
Dizziness  2 ( 22) 
Diarrhea  1 ( 11) 
Dysuria  1 ( 11) 
Lower extremity edema  1 ( 11) 
 
Table 3. Laboratory values of confirmed HPS patients on admission and during hospitalization
a 
Test 
No. of 
cases 
Median 
value 
(admission)  Range 
No. of 
cases 
Median 
maximum value 
(admission + 
hospitalization) Range 
Median 
minimum value 
(admission + 
hospitalization) Range 
Leukocyte count 
(x1,000/mm
3) 
7 6.4  3.6–14.1  9  11.4  5.7–28.1    
Hematocrit (%)  7  39.7  35.1–44.2  9  41.0  31.4–52.4     
Platelet (x1,000/mm
3) 7  84  47–186  9      60  26–429 
BUN (mg/dL)  2  7  5–9  8  26  1–56     
Creatinine (mg/dL)  3  0.8  0.6–1.0  8  2.2  1.0–3.3     
CPK (IU/L)        6  240  38–12,840     
LDH (U/L)  1  219  219
b  7 1028  32–3,775     
Albumin (g/dL)        7      2.5  1.2–3.2 
AST (U/L)  2  42  40–43  7  223  46–983     
ALT (U/L)  2  33  31–35  7  168  32–570     
Bilirubin, total (mg/dL)        7  1.1  0.8–8.0     
Bilirubin, direct (mg/dL)        7  0.6  0.1–6.5     
Amylase (U/L)        6  74  38–437     
PT (s)  1  11.7  11.7–11.7  4  13.7  11.3–22.0     
PTT (s)  1  31.2  31.2
b  4 28  27–167     
Urine leukocyte count 
(/hpf) 
5 9  6–35  9  8  1–35     
Urine erythrocyte count 
(/hpf) 
4 12  4–25  9  10  1–35     
aHPS, hantavirus pulmonary syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatinine 
phosphokinase; LDH, lactate dehydrogenase; PT, prothrombin time; PTT, partial thromboplastin time; hpf, high power field. 
bThere was only one case for this laboratory category. hantavirus. By sex, 25 (14%) of 178 females and 15 (11%)
of 133 males had IgG antibodies. The median age of the 40
antibody-positive participants was 31.5 years (range
1–79). Age group prevalence estimates ranged from 9%
(5/53, >61years of age) to 21% (6/28, 51–60 years of age).
Of 47 children, 5 (11%) <10 years of age had IgG antibod-
ies. Antibody prevalences among patients’ neighborhoods
ranged from 6% to 31% (Table 4). Two of 10 household
members of confirmed patients had IgG antibodies. Six
(15%) of the 40 infected participants had visited a con-
firmed HPS patient.
Of 119 households surveyed, 31 (26%) had at least one
member who had IgG against hantavirus (Table 4). Eight
(8%) of 96 households had two or more antibody-positive
members, while 1 (2%) of 54 households had three or
more antibody-positive members. Prevalence of antibody-
positive households (i.e., one or more antibody-positive
members) per neighborhood ranged from 8% to 73%. 
Among the 40 antibody-positive participants, occupa-
tions of those with the highest antibody prevalences were
students (14%), secretaries (13%), agricultural workers
(13%), livestock or vegetable farmers (12%), and house-
wives (11%). Among the 40 infected participants, 33
(82.5%) touched rodents, 31 (77.5%) cleaned up rodent
droppings (e.g., sweeping, mopping), and 29 (72.5%)
killed rodents after December 1, 1999. Fifteen (37.5%)
noted increased numbers of peridomestic rodents com-
pared with previous years. 
Only five (12.5%) of 40 antibody-positive participants
recalled fever or myalgia since December 1, 1999. In con-
trast, the most common symptoms reported were upper
respiratory in nature, such as rhinorrhea (45%), sore throat
(35%), and cough (22%). Moreover, of two participants
who had both IgM and IgG antibodies, one experienced
only a cough without fever, while the other was asympto-
matic.
Hospital Serosurvey
Questionnaires and serum samples were obtained from
38 directly exposed and 39 unexposed healthcare workers.
No IgM antibodies were present in the 77 workers. Only
one of 38 exposed workers had IgG antibodies. This per-
son, a medical resident, directly cared for five confirmed
HPS patients (each healthcare worker cared for an average
of 4 patients, range 1–5) for a total of approximately 15
patient-care days (group mean 43, range 1–70). His first
exposure occurred in late December 1999. While caring
for patients, he wore gloves, gown, and mask most of the
time and was not directly exposed to respiratory secre-
tions. He denied any travel to Los Santos Province after
December 1999 and had no history of exposure to rodents.
However, he was uncertain about whether he had visited
Los Santos Province before December 1999. He denied
having any febrile illness after late December 1999. Of the
remaining 37 healthcare workers who cared for HPS
patients, four (11%) were directly exposed to respiratory
secretions in the eye, nose, or mouth; 26 (70%) wore
gloves, gowns, and masks most of the time.
One unexposed worker, an operating room assistant,
also had IgG against hantavirus. She denied travel to Los
Santos Province, exposure to rodents, or febrile illness after
December 1999. However, history of travel to Los Santos
Province before December 1999 was again uncertain.
Rodent Investigation
Rodent traps were set at 13 sites, 10 of which were
homes and immediate surroundings of patients with con-
firmed and suspected HPS. One of the three remaining
sites was the home of a patient previously suspected to
have HPS who did not have antibodies to hantavirus. The
other two locations were a rural agricultural area in the
Pocri District of Los Santos Province and a late secondary
forest area (two subsites) near the town of Portabelo,
Montijo District, Veraguas Province. In all, 120 rodents
representing nine species and seven opossums (two
species) were captured (Table 5). Of the 120 rodents, 52
(43%) were caught from the 10 patient household areas. A
trap success of approximately 5% was achieved at these
homes. Only one of the six antibody-positive rodents
(Oligoryzomy fulvescens) was captured at the household of
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Table 4. Hantavirus IgG antibody-positive findings of survey participants and households by neighborhood, town, and district of 
confirmed HPS patients, Los Santos Province
a
Neighborhood  
(case no.)  Town District 
No. of persons 
tested 
No. (%) persons 
antibody positive 
No. of households 
tested 
No. (%) 
households 
antibody positive 
2  Los Angeles  Las Tablas  45  4 (8.9)  18  4 (22.2) 
4  San Jose  Las Tablas  34  5 (14.7)  11  3 (27.3) 
7  Bella Vista  Guarare  50  3 (6.0)  24  2 (8.3) 
8  San Jose  Las Tablas  48  15 (31.3)  15  11 (73.3) 
9  Santo Domingo  Las Tablas  43  6 (14.0)  15  4 (26.7) 
11  Las Tablas  Las Tablas  41  4 (9.8)  15  4 (26.7) 
12  El Cocal  Las Tablas  50  3 (6.0)  21  3 (14.3) 
Total      311  40 (12.9)  119  31 (26.1) 
aIgG, immunoglobulin G; HPS, hantavirus pulmonary syndrome. 
 a confirmed HPS case-patient (Las Tablas town); five were
captured in the Pocri District.
Discussion
We have documented the first human cases of han-
tavirus infection in Central America. A novel Panamanian
hantavirus, Choclo virus, was subsequently characterized
and is thought to be responsible for HPS during the out-
break (33). Virus genetic sequences of Choclo virus from
case-patients were identical to those from O. fulvescens
(33). 
The clinical spectrum of pulmonary disease among
HPS patients in Panama varied widely from severe disease
requiring intubation and cardiovascular support to mild
pulmonary involvement with a benign clinical course.
Extrapulmonary manifestations, such as hepatobiliary dis-
ease, hemorrhage, and central nervous system sequelae,
were also present. The case-fatality rate (0% among 9 con-
firmed cases; 25% among 12 total suspected and con-
firmed cases) was noticeably lower than that described in
Paraguay (12%), Chile (54%), and the United States (52%)
in confirmed cases (5,9,29). 
We found an antibody prevalence of 13% among
household and neighborhood members of all ages from the
outbreak foci. This figure is comparable to that found in
Paraguay, but higher than in Chile and the United States
(9,29,36). The percentages of hantavirus antibody-positive
persons and households were particularly high in San Jose,
the only town with two confirmed case-patients.
Clustering of cases of HPS was not observed, and house-
hold clustering of antibody-positive persons was infre-
quent. Only 13% of hantavirus antibody-positive persons
had a febrile illness after early December 1999, and none
had an illness compatible with HPS, which suggests that
mild infections occurred, as documented with other han-
taviruses in the United States and Chile (9,36–38). 
Person-to-person transmission of hantavirus infection
was not demonstrated during the outbreak. Infrequent clus-
tering of antibody-positive serosurvey participants by
household probably reflected common exposures to infect-
ed rodent excreta peridomestically. Furthermore, only 1 of
38 medical care workers who cared for HPS patients had
IgG antibodies, while none had IgM antibodies. Similarly,
1 of 39 workers who did not care for HPS patients had IgG
antibodies. Thus far, person-to-person transmission has
only been suggested during outbreaks caused by Andes
virus in Argentina and Chile (7–9).
Climate data from Los Santos Province clearly demon-
strated a two- to threefold increase in rainfall in September
and October 1999 when compared to similar periods in the
previous 4 years (Figure 2). Such atypical rainfall patterns
may have led to increases in rodent populations, which led
to more frequent contact between infected rodents and
humans and subsequent human infection. Many residents
of patient-neighborhoods of Las Tablas reported an unusu-
ally large number of rodents from December 1999 through
January 2000. Similar patterns of environmental change
followed by outbreaks of human disease have been
observed in the United States and South America
(29,39,40). 
Ecologic observations in Los Santos provided an
impression of a dry, open, and deforested region. Long-
term commercial logging, agriculture (primarily corn and
sugarcane), and animal husbandry practices (mainly cattle
and horses) have contributed to the deforestation process.
The rodent species most closely associated with corn and
sugarcane fields, Zygodontomys brevicauda cherriei, is a
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Table 5. List of species of rodents and opossums captured at 13 trapping sites in Los Santos and Veraguas Provinces, Panama, 
February–March 2000, and antibody results 
Rodent species (common name)  No. captured  No. hantavirus antibody-positive 
Zygodontomys brevicauda cherriei (cane rat)  50  4 
Sigmodon hispidus (hispid cotton rat)  20  0 
Oligoryzomys fulvescens (fulvous pigmy rice rat)  15  2 
Oryzomys couesi (Coues’s rice rat)  14  0 
Mus musculus (house mouse)  9  0 
Liomys adspersus (Panamanian spiny pocket mouse)  8  0 
Oryzomys concolor (colored rice rat)  2  0 
Proechimys semispinosus (silky spiny rat)  1  0 
Rattus rattus (black rat)  1  0 
Marmosa mexicana. (Mexican mouse opossum)  4  0 
Marmosa robinsoni (Robinson’s mouse opossum)  3  0 
Figure 2. Comparison of monthly rainfall in 1999 with the average
monthly rainfall from 1995 to 1998, Los Santos Province, Panama. likely reservoir host for a new hantavirus, Calabazo virus
(33). O. fulvescens, the likely reservoir for Choclo virus,
was found in grass of varying heights near human habita-
tion and in cattle and horse pastures. Given the observed
habitat associations of these two species, agriculture and
animal husbandry practices in the Los Santos regions may
have had a positive effect on populations of rodents asso-
ciated with hantaviruses and may continue to augment the
risk for HPS as the human population increases.
The social and economic impact of this outbreak was
substantial. The cancellation of Carnival, one of Panama’s
most celebrated festivals, had  financial effects on resi-
dents of Las Tablas. Nevertheless, the public health impact
of holding Carnival could also have been substantial, given
the potential for rodent exposure among thousands of vis-
itors and participants. 
In conclusion, this outbreak resulted in the first docu-
mented cases of human hantavirus infections in Central
America. Although cases were not reported from other dis-
tricts of Los Santos or other provinces of Panama during
the investigation, surveillance for HPS nationwide should
continue, as serologic testing capabilities have since been
implemented in Panama. More extensive sampling of
rodent populations would help identify other areas in
Panama with large numbers of O. fulvescens that could
place residents at risk for Choclo virus infection.
Longitudinal studies of rodents, particularly those species
implicated as reservoir hosts, will be necessary to monitor
the fluctuation and distribution of rodent population num-
bers over time and their correlation with human infection
(41). Educational campaigns promoting risk reduction,
such as proper clean-up of rodent excrement, sealing
homes against the entry of rodents, and other rodent-proof-
ing techniques, should continue as additional cases of HPS
are reported in Panama. 
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